Market revenue in 2023 | USD 854.8 million |
Market revenue in 2030 | USD 782.8 million |
Growth rate | -1.2% (CAGR from 2023 to 2030) |
Largest segment | Opioids |
Fastest growing segment | NSAIDs and Others |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Opioids was the largest segment with a revenue share of 25.84% in 2023. Horizon Databook has segmented the Germany cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Rising incidence of cancer in this country is one of the major factors anticipated to accelerate demand for supportive cancer care drugs in Germany. Lung cancer is the most common cause of death in this country. According to GLOBOCAN, in 2020, around 628,519 total cancer cases were reported in Germany, of which 69,697 were breast cancer and 62,641 were prostate cancer cases.
In addition, the prevalence of cancer and chronic pain is high in Germany. The medical tourism industry is also booming due to affordable treatment of cancer in the region. The region is one of the leaders in terms of development of cancer chemotherapy regimens. Thus, adoption of chemotherapy is increasing in this region. This further leads to high adoption of chemotherapy-associated supportive care drugs in the region.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Germany cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account